Trial intelligence / Profile preview

Phase 3 randomized double-blind placebo-controlled study of ivosidenib plus azacitidine in untreated IDH1-mutated acute myeloid leukemia

CTR20181920Phase 3Active

Sponsor

Agios Pharmaceuticals

Start

Jul 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Countries

1